English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

STELLA-LONG TERM, a 3-year post-marketing surveillance study, evaluated the safety and effectiveness of the sodiumglucose cotransporter 2 inhibitor ipragliflozin in Japanese type 2 diabetes mellitus (T2DM) patients. Final results in the safety (n = 6697) and effectiveness populations (n = 5625) were analyzed by stratifying patients by baseline estimated glomerular filtration rate (eGFR, mL/min/1.73 m 2 ) into four subgroups (≥90, 60 to &lt;90, 45 to &lt;60, and &lt;45) and two subgroups (≥60 and &lt;60). Adverse drug reaction (ADR) incidence, and changes from baseline in glycosylated hemoglobin (HbA 1c ), bodyweight, and eGFR were assessed. The percentage of patients experiencing ADRs and serious ADRs was similar across most eGFR subgroups. Polyuria/pollakiuria was the most common ADR. Renal disorders and volume depletion ADRs were more frequent in the subgroups with more severe renal impairment at baseline than in those with an eGFR of 60 to &lt;90 or ≥90 mL/min/1.73 m 2 . Bodyweight and HbA1c decreased in all subgroups, the latter by − 0.91% to − 0.40% (P &lt;0.05 vs. baseline). eGFR increased in the 45 to &lt;60 mL/min/1.73 m 2  subgroup (+ 1.42 ± 8.77 mL/min/1.73 m 2 ; P = 0.006). It decreased in the ≥90 and 60 to &lt;90 mL/min/1.73 m 2  subgroups (− 8.27 ± 13.73 and − 1.22 ± 10.34 mL/min/1.73 m 2 ; P &lt;0.001), but not to &lt;60 mL/min/1.73 m 2 . In conclusion, there were no new or unexpected safety findings in Japanese patients treated with ipragliflozin for T2DM, and long-term sustained improvements in HbA 1c  and bodyweight were observed regardless of the presence of renal impairment.

saharnyj diabet

Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)